UNSPSC 51171708: Diphenoxylate

This classification denotes an antidiarrheal agent with the molecular formula C30H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73312P173G, chemically known as 2,2-diphenyl-4-(4-carbethoxy-4-phenylpiperidino)butyronitrile but generally known as diphenoxylate, which bears US NIH Compound Identifier 13505. European Medicines Agency schedules Diphenoxylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07212MIG.

UNSPSC 51171708 Diphenoxylate is a Commodity code covering pharmaceutical active ingredients and finished pharmaceutical products procured by state and local jurisdictions for criminal justice substance-abuse monitoring, public-health pharmacy benefit programs, and cooperative purchasing agreements serving multistate health systems. Recent solicitations show state and local buyers sourcing drug-testing reagents and pharmaceutical products through RFPs and cooperative purchasing vehicles that bundle diphenoxylate with other generic pharmaceuticals and over-the-counter products. The code captures both direct pharmaceutical procurement (specimen-screening and confirmation reagents used in offender drug testing) and participation in broader multistate cooperative pharmaceutical agreements that establish pricing and supply chains for generic products across government agencies.

Activity under the code is concentrated in Texas and Minnesota, driven by two distinct procurement models. The Collin County Community Supervision and Corrections Department issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services with a response deadline of July 23, 2026, seeking immunoassay screening and LC/MS/MS or GC/MS confirmation services (approximately 25,031 annual tests) at an estimated contract value of $600,000 over two years with optional renewals through 2031. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP due March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with products to become available in the market by May 15, 2026 and awarded vendor agreements effective July 1, 2026. The Texas Health and Human Services Commission also posted RFI HHS0017013 on March 27, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs, signaling exploratory procurement that may lead to formal solicitations. Most recent activity spans criminal-justice and health-benefit program procurement, with multistate cooperative purchasing representing the largest-volume procurement vehicle.